Login to Your Account

70% of ODD Requests Ok'd

Shares of Advaxis Plummet on FDA Orphan Drug Denial

By Donna Young

Thursday, June 4, 2009
Shares of Advaxis Inc. plunged 36.6 percent Wednesday after the North Brunswick, N.J.-based company revealed that the FDA had denied its orphan drug designation application for ADXS11-01 (formerly Lovaxin-C) as an immunotherapy for invasive cervical cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription